Navigation Links
Regeneron Announces FDA Approval of EYLEA™ (aflibercept) Injection for the Treatment of Wet Age-Related Macular Degeneration
Date:11/18/2011

ts in EYLEA.

The recommended dose for EYLEA is 2 mg administered by intravitreal injection every four weeks (monthly) for the first 12 weeks (3 months), followed by 2 mg once every eight weeks (2 months).  Although EYLEA may be dosed as frequently as 2 mg every four weeks (monthly), additional efficacy was not demonstrated when EYLEA was dosed every four weeks compared to every eight weeks.

There is a potential risk of arterial thromboembolic events (ATEs) following use of intravitreal VEGF inhibitors, including EYLEA, defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).  The incidence of ATEs with EYLEA in clinical trials was low (1.8%).

Serious adverse reactions related to the injection procedure have occurred in less than 0.1% of intravitreal injections with EYLEA and include endophthalmitis, traumatic cataract, and increased intraocular pressure.

About the VIEW 1 and VIEW 2 Clinical StudiesThe safety and efficacy of EYLEA were assessed in two randomized, multi-center, double-masked, active-controlled studies in patients with wet AMD.  A total of 2412 patients were treated and evaluable for efficacy (1817 with EYLEA) in the two studies (VIEW 1 and VIEW 2). In each study, patients were randomly assigned in a 1:1:1:1 ratio to one of four dosing regimens: 1) EYLEA administered 2 mg every eight weeks following three initial monthly doses (EYLEA 2Q8); 2) EYLEA administered 2 mg every four weeks (EYLEA 2Q4); 3) EYLEA 0.5 mg administered every four weeks (EYLEA 0.5Q4); and 4) ranibizumab administered 0.5 mg every four weeks (ranibizumab 0.5Q4).  Patient ages ranged from 49 to 99 years with a mean of 76 years.

In both studies, the primary efficacy endpoint was the proportion of patients who maintained vision, defined as losing fewer than 15 letters of visual acuity at week 52 compared to baseline.  Data are available through week 52.
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Sanofi and Regeneron Report Positive Preliminary Phase 2 Program Results for Anti-PCSK9 Antibody in Hypercholesterolemia
2. Regeneron Pharmaceuticals Announces Pricing of Offering of Convertible Senior Notes due October 1, 2016
3. Regeneron Ranked by Science Magazine as the #2 Employer in the Global Biopharmaceutical Industry
4. Regeneron Announces Clinical Presentations at ASRS 2011 Annual Meeting
5. Regeneron Reports Second Quarter 2011 Financial and Operating Results
6. Sanofi and Regeneron Report Positive Phase 2b Trial Results with Sarilumab in Rheumatoid Arthritis
7. Trading in Regeneron Common Stock Halted
8. Regeneron Reports First Quarter 2011 Financial and Operating Results
9. Regeneron Announces Presentation at the Bank of America Merrill Lynch 2011 Health Care Conference
10. Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Second Phase 3 Study in Central Retinal Vein Occlusion
11. Regeneron and Bayer Announce Start of Phase 3 Clinical Program in Diabetic Macular Edema
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... , May 17, 2013 The power of ... important ways in which mankind depends on the plant ... Garden,s multifaceted exhibition Wild Medicine: Healing ... on view from May 18 through September 8, ... The featured exhibition,s many attractions include a re-creation ...
(Date:5/17/2013)... 2013  Sorrento Therapeutics, Inc. (OTCBB: SRNE; or ... Small Business Technology Transfer Research (STTR) grant (#1R42AI098182-02) ... Diseases (NIAID), a division of the National Institutes ... human antibody therapeutics to combat Staphylococcus aureus ... including methicillin-resistant S. aureus (MRSA), was ...
(Date:5/17/2013)... May 17, 2013   Shareholder rights attorneys  at ... Pharmaceutical, Inc. (NASDAQGS: AVEO) securities has filed a complaint ... Massachusetts .  The complaint alleges that ... Exchange Act of 1934 (the "Exchange Act") between January ... (Logo: http://photos.prnewswire.com/prnh/20130103/MM36754LOGO ) ...
Breaking Medicine Technology:Wild Medicine On View at The New York Botanical Garden Through Sept. 8 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 2Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 3Sorrento Therapeutics, Inc. announces its approach to developing human antibody therapeutics against MRSA receives continued support from the National Institute of Allergy and Infectious Diseases 4Aveo Pharmaceuticals, Inc. Sued by Investor 2Aveo Pharmaceuticals, Inc. Sued by Investor 3
... 22 Omeros Corporation (Nasdaq: OMER ), ... products focused on inflammation and disorders of the central ... a webcast conference call Monday afternoon, October 25, 2010 ... update. Gregory A. Demopulos, M.D., chairman and chief executive ...
... ENDP ) today announced that it will present at the ... 2010, at 2:10 p.m. EDT.  Blaine Davis, vice president, corporate affairs ... There will be a live webcast and it can be ... section. About Endo Endo ...
Cached Medicine Technology:Omeros to Host Conference Call Monday, October 25 at 4:00 p.m. ET To Provide Corporate Update 2
(Date:5/20/2013)... In celebration of National Women’s Health Week and ... The Feinstein Institute for Medical Research and ... in Science and Medicine (AWSM) , hosted its second ... business and community leaders from the region attended the ... science. , “Women face unique barriers to success ...
(Date:5/20/2013)... Posterior fossa subdural hematoma (PFSDH) is a serious and ... But with appropriate treatment, there,s an excellent chance of ... reports a study in the May issue of ... Congress of Neurological Surgeons . The journal is published ... of Wolters Kluwer Health . , The results ...
(Date:5/20/2013)... Hospital emergency departments play a growing role in the ... of hospital admissions and serving increasingly as an advanced ... new RAND Corporation study. , While often targeted as ... rooms remain an important safety net for Americans who ... in slowing the growth of health care costs, according ...
(Date:5/20/2013)... it about toothpaste that transforms the sweet flavor of ... to that mysterious sensory phenomenon in colorful, animated ... Chemical Society,s award-winning Bytesize Science video series ... world,s largest scientific society, explains that the mainstay ingredients ... or SLS for short. When you brush your teeth, ...
(Date:5/20/2013)... As high schoolers prepare for final exams, teens ... -- a prescription stimulant or amphetamine -- to gain ... poll shows only one in 100 parents of teens ... a study drug., Study drugs refer to stimulant medications ... disorder (ADHD); commonly prescribed medicines in this category include ...
Breaking Medicine News(10 mins):Health News:North Shore-LIJ's Feinstein Institute Celebrates Women in Science During National Women’s Health Week 2Health News:North Shore-LIJ's Feinstein Institute Celebrates Women in Science During National Women’s Health Week 3Health News:Study supports 'aggressive' treatment for posterior fossa hematoma in newborns 2Health News:Study supports 'aggressive' treatment for posterior fossa hematoma in newborns 3Health News:Hospital emergency departments gaining in importance, study finds 2Health News:Hospital emergency departments gaining in importance, study finds 3Health News:1 in 10 teens using 'study drugs,' but parents aren't paying attention 2
... Kids treated more than 150 days after an Anterior Cruciate ... including medial meniscal tears, say researchers presenting at the American ... Francisco, CA. "In our research, children who had delayed ... to have an increased chance of also having a medial ...
... FRANCISCO, CA When it comes to treating people ... with the use of magnetic resonance images (MRI), according ... Society for Sports Medicine,s (AOSSM) Specialty Day in San ... sample of volunteers without any hip pain, and discovered ...
... appeared to not affect injury rates and performance in ... Orthopaedic Society for Sports Medicine,s Specialty Day in San ... an injury and enhanced performance in baseball pitchers is ... Carl W. Nissen, MD of Elite Sports Medicine and ...
... (HealthDay News) -- ,There,s little evidence linking disease severity ... in HIV-positive children and teens infected around the time ... experts were concerned that more severe HIV illness -- ... specific highly active antiretroviral therapy regimens might increase the ...
... By Steven Reinberg HealthDay Reporter , FRIDAY, Feb. ... ago that a strange new strain of flu first appeared ... States and eventually much of the globe. The H1N1 ... it proved particularly dangerous to children and younger adults -- ...
... Dentistry at the University of Alberta is hoping its latest ... that target certain types of cancers. , The discovery ... fellow Nicolas Coquelle has shed light on what happens in ... a DNA repair enzyme called polynucleotide kinase/phosphatase, or PNKP. This ...
Cached Medicine News:Health News:Delaying ACL reconstruction in kids may lead to higher rates of associated knee injuries 2Health News:HIV Severity, Treatment Unrelated to Kids' Mental Woes: Study 2Health News:H1N1 'Swine' Flu Makes a Comeback in Mexico 2Health News:New understanding of DNA repair could eventually lead to cancer therapy 2
... is an automated microplate analyzer ... microplate techniques. Open architecture design ... many manufacturers' microplate assays and ... R.I.A. and I.F.A. methods as ...
... MAP D-Type can combine a number ... 180 microplates on a simple to ... instrument is a multifunctional stand-alone device ... larger robotic systems. Custom and standard ...
... provides a fast, accurate assessment of,patient ... patented,state-of-the-art optics yield accurate measurements of ... total hemoglobin. When,used in combination with ... gives a comprehensive and complete assessment ...
The Stat Profile pHOx CO-Oximeter is intended for use in those situations where a more comprehensive profile beyond the measured hematocrit, hemoglobin, and SO2% offered by the Stat Profile pHOx ...
Medicine Products: